Key facts
- This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jan 2025, 16:11.
Christopher Benecchi - 16 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- SAGE
- Reported as of
- 16 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2025, 16:11:21 UTC
- Prior SEC filing
- 14 Nov 2024
- Next SEC filing
- 14 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- Brandon Marsh, attorney in fact for Christopher Benecchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 21 Jan 2025.
Change
- Previous filing in this sequence was filed on 14 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +81%
- Price
- $0.000000
- Shares after
- 44,737
- Date
- 16 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 16 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $6.97
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of shares of common stock issuable under 20,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on January 16, 2026.
Footnote F2
The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 10,000 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 30,000 shares vesting in 36 equal monthly installments thereafter.